Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Patient-Focused Guidance Writing: FDA Aiming For 'Sweet Spot' In Advice

Executive Summary

US FDA’s first guidance on patient data collection methods will be ready by June, and agency wants to get the tone right from the start; agency assures stakeholders it will be “flexible” on accepting new tools.


Related Content

Patient-Focused Drug Development: US FDA 'Needs To Be Brave,' Tell Sponsors What Works Best
US FDA’s Patient Input Guidance Opens Door Wider To Social Media Data Collection
From Listening To Advising: The Maturation Of US FDA's Patient-Focused Drug Development Program
Oncology PROs: Limited Use Due To Small Trials, Fast Drug Development


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts